Big Pharma, Bigger Milestones
Does Big Pharma tend to make higher milestone payments in development deals than other types of licensees?
You may also be interested in...
Productivity in biotech is a better problem to have than its opposite-but paying the higher-than-expected development costs makes it still a problem. Thanks to a variety of new project financing sources, and a particularly clever approach to amending its alliance with GlaxoSmithKline, Exelixis is fact trying to turn research productivity into a source of non-dilutive capital.
Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.
Teachers are among the 500 to 700 consumers responding to monthly nationwide survey on nutritional supplement usage Pharmavite started in April 2020 as novel coronavirus pandemic began widespread impact across US, says chief marketing officer Rhonda Hoffman.